Breast and Ovarian Cancer Program (Project-007)

乳腺癌和卵巢癌计划（项目-007）

• 批准号: 9114529
• 负责人: Adrian V Lee
• 金额: $ 3.47万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9114529
• 关键词: Award; Basic Science; Bioinformatics; Biology; Biometry; Breast; Breast Cancer Prevention; Cancer Biology; Cancer Center Support Grant; Cancer Immunology Science; Cessation of life; Chemicals; Clinical; Clinical Data; Clinical Protocols; Clinical Research; Clinical Trials; Collaborations; Complement; Cytometry; Data; Dependency; Development; Diagnostic and Statistical Manual of Mental Disorders; Diagnostic tests; Disseminated Malignant Neoplasm; Dreams; Drug Kinetics; Epigenetic Process; Evolution; Fostering; Foundations; Funding; Genetic Screening; Grant; Head and Neck Cancer; Heterogeneity; Immunologic Monitoring; Incidence; Individual; International; Investigational Drugs; Journals; Knowledge; Laboratories; Lead; Lobular; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of ovary; Mission; Molecular; Monitor; NCI Center for Cancer Research; Nature; Noninfiltrating Intraductal Carcinoma; Ovarian; Paper; Pathology; Patient Care; Peer Review Grants; Pharmacodynamics; Phase; Pilot Projects; Prevention; Prevention program; Prognostic Marker; Protocols documentation; Publications; Research; Research Personnel; Research Support; Resource Sharing; Risk Reduction; Role; Roswell Park Cancer Institute; Safety; Schools; Science; Services; Site; Specialized Program of Research Excellence; Strategic Planning; System; Systemic Therapy; Technology; Therapeutic; Therapeutic Intervention; Tissue imaging; Tissues; Translating; Translational Research; Universities; University of Pittsburgh Cancer Institute; Vision; Woman; Work; abstracting; acronyms; animal facility; anticancer research; base; biobehavior; cancer epidemiology; cancer genomics; cancer initiation; cancer prevention; cancer proteomics; cellular imaging; companion diagnostics; data management; diagnostic biomarker; forging; improved; in vivo imaging; individualized prevention; interest; malignant breast neoplasm; meetings; melanoma; member; new therapeutic target; next generation; novel; novel diagnostics; oncology program; personalized medicine; prognostic assays; programs; response; translational study; tumor; tumor progression; virology

Abstract: Breast and Ovarian Cancer Program (BOCP) The mission of the Breast and Ovarian Cancer Program (BOCP), a newly established Program being proposed in this UPCI Cancer Center Support Grant renewal, is to reduce the incidence and death from women's cancer with a focus on breast and ovarian malignancies. This mission is achieved through the development and fostering of basic, translational, and clinical research in breast and ovarian cancer and aimed at translating novel discoveries into improved patient care. The BOCP has four main research themes: 1) basic cancer biology, 2) diagnostic and prognostic markers, 3) prevention, and 4) molecular therapeutics. The BOCP specific aims are to: 1) investigate mechanisms of cancer initiation and progression, 2) identify and validate new diagnostic and prognostic markers, 3) examine the role of tumor evolution and heterogeneity in progression and response to therapy, 4) discover the phenotypic and genotypic dependencies of metastatic cancer, and 5) translate knowledge of the biology into personalized prevention and treatment. The BOCP has 42 members representing 12 academic departments and 3 schools of the University of Pittsburgh. Based upon a retrospective analysis of historical data from January 2010 to April 2014, BOCP members authored or co- authored 517 cancer-related publications, of which 31% resulted from intra-programmatic and 30% from inter- programmatic collaborations. Approximately 54% of the papers represent collaborations with external investigators. Research in the BOCP is supported by an NCI Specialized Program of Research Excellence (SPORE) in Ovarian Cancer shared with Roswell Park Cancer Institute (RPCI), as well as individual federal grants, foundation awards, and philanthropy. BOCP members currently receive a total of $8.2 M in annual direct funding, including $2.6 M from the NCI and $2.1 M in other peer-reviewed grant support. A highly collaborative and interactive group, BOCP members meet regularly at work-in-progress meetings, journal clubs, and a yearly retreat. In addition, the BOCP forges relationships with other programs to enhance the multi-disciplinary nature of breast and ovarian cancer research at UPCI. UPCI support, including Clinical Protocol and Data Management and Shared Resources, specifically the Animal Facility, Biostatistics Facility, Cancer Bioinformatics Services, Cancer Genomics Facility, Cancer Pharmacokinetics and Pharmacodynamics Facility, Cancer Proteomics Facility, Cell and Tissue Imaging Facility, Chemical Biology Facility, Cytometry Facility, Immunological Monitoring and Cellular Products Laboratory, In Vivo Imaging Facility, Investigational Drug Services, and Tissue and Research Pathology Services facilitates and enhances BOCP research.

摘要：乳腺癌和卵巢癌计划（BOCP） 乳腺癌和卵巢癌计划（BOCP）的使命，一个新成立的计划正在提出 在这个UPCI癌症中心支持赠款更新，是为了减少妇女癌症的发病率和死亡率 重点是乳腺和卵巢恶性肿瘤这一使命是通过开发和 促进乳腺癌和卵巢癌的基础、转化和临床研究，旨在将 新的发现来改善病人护理。BOCP有四个主要研究主题：1）基础癌症 生物学，2）诊断和预后标志物，3）预防，和4）分子治疗。BOCP 具体目标是：1）研究癌症发生和进展的机制，2）识别和验证 新的诊断和预后标志物，3）检查肿瘤演变和异质性在 进展和对治疗的反应，4）发现转移性肿瘤的表型和基因型依赖性， 癌症，以及5）将生物学知识转化为个性化的预防和治疗。BOCP已经 代表匹兹堡大学12个学术部门和3个学院的42名成员。基于 回顾性分析了2010年1月至2014年4月的历史数据，BOCP成员撰写或共同撰写了 撰写了517篇与癌症相关的出版物，其中31%来自计划内，30%来自计划间。 方案合作。大约54%的论文代表与外部合作 investigators. BOCP的研究得到了NCI卓越研究专业计划的支持 （孢子）在卵巢癌与罗斯韦尔公园癌症研究所（RPCI），以及个人联邦共享 赠款、基金会奖励和慈善事业。BOCP成员目前每年总共收到820万美元 直接资助，包括来自NCI的260万美元和其他同行评审赠款支持的210万美元。一个高度 协作和互动小组，BOCP成员定期举行工作进展会议，期刊 俱乐部和年度静修此外，BOCP与其他计划建立关系，以加强 乳腺癌和卵巢癌研究的多学科性质。UPCI支持，包括临床 方案和数据管理以及共享资源，特别是动物机构、生物统计机构， 癌症生物信息学服务，癌症基因组学设施，癌症药代动力学和药效学 设施，癌症蛋白质组学设施，细胞和组织成像设施，化学生物学设施，细胞计数 机构，免疫学监测和细胞制品实验室，体内成像机构，研究 药物服务，组织和研究病理学服务促进和加强BOCP研究。